Search
Cellectis SA
CLLSAdd to Watchlist
3.190USD
-0.215-6.31%
Close 08-24 16:00（ET）
230.76MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-24The current earnings forecast score of Cellectis SA is 8.67, ranking 75 out of 379 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 10.00 and a low of 4.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
7.500
Target Price
+120.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cellectis SA
CLLS
6
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
Kymera Therapeutics Inc
KYMR
24
IQVIA Holdings Inc
IQV
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cellectis SA's expected revenue for the next quarter?
Cellectis SA's expected revenue is 14.04M.
What is Cellectis SA's price target?
Analysts forecast that Cellectis SA's price target is USD 7.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Cellectis SACLLS's recent earnings per share performed?
The market expectation was USD -0.22, while Cellectis SACLLS's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for Cellectis SA?
Based on the ratings of Cellectis SA's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.